Literature DB >> 20979179

Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.

Alexandra Walsh1, David R Kelly, Yoginder N Vaid, Lee M Hilliard, Gregory K Friedman.   

Abstract

Renal medullary carcinoma (RMC) is a rare and aggressive malignancy seen primarily in patients with sickle-cell trait. We report a complete response to carboplatin, paclitaxel, and gemcitabine in a patient with advanced metastatic RMC.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20979179     DOI： 10.1002/pbc.22611

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  15 in total

1.  Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil.

Authors:  Marina Cavalcanti Maroja Silvino; Camila Motta Venchiarutti Moniz; Gustavo Henrique Munhoz Piotto; Sheila Siqueira; Ariel Galapo Kann; Carlos Dzik
Journal:  Rare Tumors       Date:  2013-08-20

Review 2.  Management of Atypical Renal Cell Carcinomas.

Authors:  Bobby C Liaw; Reza Mehrazin; Charles Baker; John P Sfakianos; Che-Kai Tsao
Journal:  Curr Treat Options Oncol       Date:  2017-09-14

Review 3.  Negative health implications of sickle cell trait in high income countries: from the football field to the laboratory.

Authors:  Nigel S Key; Philippe Connes; Vimal K Derebail
Journal:  Br J Haematol       Date:  2015-03-07       Impact factor: 6.998

4.  Clinical and computed tomography imaging features of renal medullary carcinoma: A report of six cases.

Authors:  Zhenshan Shi; Qian Zhuang; Ruixiong You; Yueming Li; Jian Li; Dairong Cao
Journal:  Oncol Lett       Date:  2015-11-09       Impact factor: 2.967

Review 5.  Recent Advances in Renal Medullary Carcinoma.

Authors:  Yongdong Su; Andrew L Hong
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

6.  Renal medullary carcinoma: a nearly fatal malignancy specifically affecting patients with a so-called benign condition.

Authors:  Yamila Goenaga-Vázquez; Gloria Colón; Nilka Barrios; María Correa
Journal:  CEN Case Rep       Date:  2018-02-02

Review 7.  Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact.

Authors:  Brandon J Manley; Abraham Ari Hakimi
Journal:  Curr Opin Urol       Date:  2016-09       Impact factor: 2.309

8.  A prospective study of pediatric and adolescent renal cell carcinoma: A report from the Children's Oncology Group AREN0321 study.

Authors:  James I Geller; Nicholas G Cost; Yueh-Yun Chi; Brett Tornwall; Mariana Cajaiba; Elizabeth J Perlman; Yeonil Kim; Elizabeth A Mullen; Richard D Glick; Geetika Khanna; Najat C Daw; Peter Ehrlich; Conrad V Fernandez; Jeffrey S Dome
Journal:  Cancer       Date:  2020-09-14       Impact factor: 6.860

9.  Response to radiation in renal medullary carcinoma.

Authors:  Alexandra M Walsh; John B Fiveash; Alyssa T Reddy; Gregory K Friedman
Journal:  Rare Tumors       Date:  2011-07-21

10.  Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, Doxorubicin, and Cisplatin chemotherapy.

Authors:  Ali Imran Amjad; Hira Ali; Leonard J Appleman; Jodi Maranchie; Stephen Jackman; Anil Parwani; Rajiv Dhir; Somak Roy; Rahul A Parikh
Journal:  Case Rep Oncol Med       Date:  2014-08-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.